E 3174

Drug Profile

E 3174

Alternative Names: EXP 3174

Latest Information Update: 29 Mar 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Merck Sharp & Dohme
  • Class Imidazoles; Tetrazoles
  • Mechanism of Action Angiotensin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Reperfusion injury

Most Recent Events

  • 18 Oct 1999 Preclinical development for Arrhythmias in USA (Unknown route)
  • 30 Mar 1998 A preclinical study has been added to the pharmacokinetics section
  • 26 Mar 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top